Pharmacovigilance Archives

Migrating Your Safety Database: What Nobody Tells You Before You Start

The Migration Narrative You Hear vs. Reality The conventional narrative around pharmacovigilance database migration is straightforward: extract data from the legacy system, validate it during a transition window, and load it into the new platform. Timeline estimates range from three...

June 5, 2026

Duplicate Literature Records in PV: The Compliance Risk No One Talks About, Until Inspection

Blog Literature Management

Duplicate Literature Records in PV: The Compliance Risk No One Talks About, Until Inspection

Most pharmacovigilance (PV) teams treat duplicate literature records as an operational nuisance. A few cases get merged, a few line listings get cleaned up, and the case backlog moves forward. The problem is that this view holds only until an...

May 26, 2026

How to Build a Compliant Literature Search String for Pharmacovigilance: Why Most Teams Get It Wrong

Blog Literature Management

How to Build a Compliant Literature Search String for Pharmacovigilance: Why Most Teams Get It Wrong

Ask ten pharmacovigilance (PV) teams to show you the exact Boolean search string used last week to monitor their flagship product, and most will struggle to produce it. They can produce the screening log, the case decisions, even the final...

May 20, 2026

E2B R3 Is Now Mandatory: What It Means for Your Safety Database and Submission Workflows

Blog Pharmacovigilance

E2B R3 Is Now Mandatory: What It Means for Your Safety Database and Submission Workflows

The FDA’s transition is nearly complete. As of April 1, 2026, all premarketing IND safety reports must utilize the E2B(R3) standard. We are now in the final countdown for postmarketing ICSRs; starting October 1, 2026, the FDA will move exclusively...

May 18, 2026

ICSR Processing 101: How an Adverse Event Goes from Report to Regulatory Submission

Blog Pharmacovigilance

ICSR Processing 101: How an Adverse Event Goes from Report to Regulatory Submission

Every minute, somewhere in the world, an adverse event report is being filed. EudraVigilance alone collected and managed 1,765,581 Individual Case Safety Reports (ICSRs) in 2025, taking its cumulative post-authorisation total to over 29 million reports since 2002.Across the Atlantic,...

May 15, 2026

Inside Clinevo Case Intake: One Platform for Every Adverse Event Source

Blog Case Intake

Inside Clinevo Case Intake: One Platform for Every Adverse Event Source

The first hour of a pharmacovigilance team’s day rarely involves a single, clean stream of cases. It involves audio files from a Medical Information Call Center (MICC) line, scanned MedWatch and CIOMS forms attached to emails, structured submissions from affiliate...

May 13, 2026

Pharmacovigilance (PV) Software Buyer’s Guide 2026

Blog Pharmacovigilance

Pharmacovigilance (PV) Software Buyer’s Guide 2026

The pharmacovigilance software market was valued at approximately USD 2.09 billion in 2025 and is projected to reach USD 5.06 billion by 2035, growing at a CAGR of 9.24%.That growth reflects a genuine operational shift, not a commercial trend. Regulatory...

May 12, 2026

Why Mining FAERS Alone Is a Signal Detection Blind Spot

Blog Pharmacovigilance Pharmacovigilance

Why Mining FAERS Alone Is a Signal Detection Blind Spot

For pharmacovigilance teams in the United States, the FDA Adverse Event Reporting System (FAERS) is the most familiar starting point for post-marketing safety surveillance. It is large, regulator-maintained, freely accessible through a public dashboard, and structured around the same ICH...

May 8, 2026

How Clinevo Detects Safety Signals Other Platforms Miss

Blog Pharmacovigilance Pharmacovigilance

How Clinevo Detects Safety Signals Other Platforms Miss

The global spontaneous reporting system now spans databases of extraordinary scale. FAERS alone holds 31.8 million records,EudraVigilance contained over 29.3 million ICSRs as of early 2024,and in early 2025, WHO VigiBase crossed 40 million reports. FAERS alone receives over two...

April 28, 2026

Beyond Case Counting: How AI Is Transforming Aggregate Safety Reporting.

Blog Pharmacovigilance Pharmacovigilance

Beyond Case Counting: How AI Is Transforming Aggregate Safety Reporting.

Every six months, or annually depending on the product’s EU reference date (EURD) schedule, pharmacovigilance teams begin assembling one of the most resource-intensive documents in drug safety: the Periodic Benefit-Risk Evaluation Report (PBRER), or its regulatory counterpart, the Periodic Safety...

April 27, 2026

1 2 3

Category: Pharmacovigilance

Migrating Your Safety Database: What Nobody Tells You Before You Start

Duplicate Literature Records in PV: The Compliance Risk No One Talks About, Until Inspection

How to Build a Compliant Literature Search String for Pharmacovigilance: Why Most Teams Get It Wrong

E2B R3 Is Now Mandatory: What It Means for Your Safety Database and Submission Workflows

ICSR Processing 101: How an Adverse Event Goes from Report to Regulatory Submission

Inside Clinevo Case Intake: One Platform for Every Adverse Event Source

Why Mining FAERS Alone Is a Signal Detection Blind Spot

How Clinevo Detects Safety Signals Other Platforms Miss

Beyond Case Counting: How AI Is Transforming Aggregate Safety Reporting.

Migrating Your Safety Database: What Nobody Tells You Before You Start

Duplicate Literature Records in PV: The Compliance Risk No One Talks About, Until Inspection

How to Build a Compliant Literature Search String for Pharmacovigilance: Why Most Teams Get It Wrong

E2B R3 Is Now Mandatory: What It Means for Your Safety Database and Submission Workflows

Clinevo Technologies America Inc.

Clinevo Technologies UK Limited.

Clinevo Technologies Europe B.V.

Clinevo Technologies Private Limited

Company

Clinevo Technologies America Inc.

Clinevo Technologies UK Limited.

Clinevo Technologies Europe B.V.

Clinevo Technologies Private Limited

Company